Trial · NCT03047395
A Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis ( LIMMITLESS )
NCT03047395, Phase 3, Completed, AbbVie; results first posted 2024-12-11
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis ( LIMMITLESS ). Trials, record NCT03047395. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03047395
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis ( LIMMITLESS )
- NCT number
- NCT03047395
- Status
- Completed
- Phases
- Phase 3
- Enrollment
- 2,170 participants, actual
- Lead sponsor
- AbbVie
- Conditions
- Psoriasis
- Interventions
- risankizumab
- First posted
- 2017-02-09
- Last updated
- 2024-12-11
- Other registries' IDs
- eudract:2016-003046-87
- Results first posted
- 2024-12-11
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Participants With Serious Adverse Events and Non-Serious Adverse Events | Median follow-up time of 1905 days | An adverse event is defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. The investigator assessed the relationship of each event to the use of study drug as either probably related, possibly related, probably not related or not related. A serious adverse event is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the subject and may require medical or surgical intervention to prevent any of the outcomes listed above. |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Participants With Serious Adverse Events and Non-Serious Adverse Events | Median follow-up time of 1905 days | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.gov
Results by group2
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Serious Adverse Events and Non-Serious Adverse Events | Risankizumab 150 mg | Serious Adverse Events | 435 | Participants | |
| Number of Participants With Serious Adverse Events and Non-Serious Adverse Events | Risankizumab 150 mg | Non-serious Adverse Events | 1215 | Participants |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Risankizumab 150 mg | 2,170 | |
| Overall Study | COMPLETED | Risankizumab 150 mg | 1,601 | |
| Overall Study | NOT COMPLETED | Risankizumab 150 mg | 569 |
Source ClinicalTrials.gov
Adverse events396
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | COVID-19 | Infections and infestations | Risankizumab 150 mg | 360 | 2,170 | 384 |
| other | NASOPHARYNGITIS | Infections and infestations | Risankizumab 150 mg | 480 | 2,170 | 833 |
| other | UPPER RESPIRATORY TRACT INFECTION | Infections and infestations | Risankizumab 150 mg | 312 | 2,170 | 467 |
| other | ARTHRALGIA | Musculoskeletal and connective tissue disorders | Risankizumab 150 mg | 217 | 2,170 | 267 |
| other | BACK PAIN | Musculoskeletal and connective tissue disorders | Risankizumab 150 mg | 124 | 2,170 | 142 |
| other | HEADACHE | Nervous system disorders | Risankizumab 150 mg | 134 | 2,170 | 211 |
| other | HYPERTENSION | Vascular disorders | Risankizumab 150 mg | 227 | 2,170 | 245 |
| serious | ANAEMIA | Blood and lymphatic system disorders | Risankizumab 150 mg | 3 | 2,170 | 4 |
| serious | FEBRILE NEUTROPENIA | Blood and lymphatic system disorders | Risankizumab 150 mg | 1 | 2,170 | 1 |
| serious | HAEMOLYSIS | Blood and lymphatic system disorders | Risankizumab 150 mg | 1 | 2,170 | 1 |
1 to 10 of 396Source ClinicalTrials.gov
See all 396 adverse eventsAdverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Risankizumab 150 mg | 28 | 2,170 |
| Total, other adverse events | Risankizumab 150 mg | 1,215 | 2,170 |
| Total, serious adverse events | Risankizumab 150 mg | 435 | 2,170 |
Source ClinicalTrials.gov
Papers4
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03047395
GET https://conductscience.org/api/trials/v1/NCT03047395/events?page=2